|
1
|
Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents.
|
Naunyn Schmiedebergs Arch Pharmacol
|
2001
|
1.14
|
|
2
|
[Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor.
|
Br J Pharmacol
|
2002
|
1.14
|
|
3
|
Structure-activity studies on neuropeptide S: identification of the amino acid residues crucial for receptor activation.
|
J Biol Chem
|
2006
|
1.13
|
|
4
|
Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor.
|
Med Res Rev
|
2010
|
1.09
|
|
5
|
Anxiolytic-like effect of neuropeptide S in the rat defensive burying.
|
Peptides
|
2008
|
1.08
|
|
6
|
Synthesis and biological activity of human neuropeptide S analogues modified in position 5: identification of potent and pure neuropeptide S receptor antagonists.
|
J Med Chem
|
2009
|
1.08
|
|
7
|
In vitro and in vivo pharmacological characterization of the neuropeptide s receptor antagonist [D-Cys(tBu)5]neuropeptide S.
|
J Pharmacol Exp Ther
|
2008
|
1.05
|
|
8
|
UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor.
|
CNS Drug Rev
|
2005
|
1.01
|
|
9
|
Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with metastatic gastric cancer (MGC).
|
Am J Clin Oncol
|
2006
|
1.01
|
|
10
|
Molecular signature detection of circulating tumor cells using a panel of selected genes.
|
Cancer Lett
|
2008
|
0.97
|
|
11
|
Further studies on the pharmacological profile of the neuropeptide S receptor antagonist SHA 68.
|
Peptides
|
2010
|
0.97
|
|
12
|
A new ligand for the urotensin II receptor.
|
Br J Pharmacol
|
2002
|
0.95
|
|
13
|
Synthesis and biological activity of human neuropeptide S analogues modified in position 2.
|
J Med Chem
|
2008
|
0.95
|
|
14
|
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies.
|
J Pharmacol Exp Ther
|
2007
|
0.95
|
|
15
|
Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior.
|
J Neurosci
|
2004
|
0.95
|
|
16
|
Chemotherapy use at the end of life. A retrospective single centre experience analysis.
|
Tumori
|
2011
|
0.93
|
|
17
|
Further studies at neuropeptide s position 5: discovery of novel neuropeptide S receptor antagonists.
|
J Med Chem
|
2009
|
0.92
|
|
18
|
Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24.
|
Eur J Pharmacol
|
2009
|
0.92
|
|
19
|
Pharmacological profile of nociceptin/orphanin FQ receptors.
|
Clin Exp Pharmacol Physiol
|
2002
|
0.89
|
|
20
|
[Arg(14),Lys(15)]nociceptin, a highly potent agonist of the nociceptin/orphanin FQ receptor: in vitro and in vivo studies.
|
J Pharmacol Exp Ther
|
2002
|
0.89
|
|
21
|
Quality of life in colon cancer patients with skin side effects: preliminary results from a monocentric cross sectional study.
|
Health Qual Life Outcomes
|
2010
|
0.88
|
|
22
|
Structure-activity study at positions 3 and 4 of human neuropeptide S.
|
Bioorg Med Chem
|
2008
|
0.88
|
|
23
|
Altered anxiety-related behavior in nociceptin/orphanin FQ receptor gene knockout mice.
|
Peptides
|
2007
|
0.87
|
|
24
|
Pharmacological characterization of tachykinin tetrabranched derivatives.
|
Br J Pharmacol
|
2014
|
0.86
|
|
25
|
Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide.
|
Bioorg Med Chem
|
2009
|
0.85
|
|
26
|
Gemcitabine Plus Nab-Paclitaxel as Second-Line and Beyond Treatment for Metastatic Pancreatic Cancer: a Single Institution Retrospective Analysis.
|
Rev Recent Clin Trials
|
2015
|
0.84
|
|
27
|
Structure-activity relationship study on human urotensin II.
|
J Pept Sci
|
2005
|
0.84
|
|
28
|
[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor.
|
J Pharmacol Exp Ther
|
2004
|
0.83
|
|
29
|
Targeting VEGF-VEGFR Pathway by Sunitinib in Peripheral Primitive Neuroectodermal Tumor, Paraganglioma and Epithelioid Hemangioendothelioma: Three Case Reports.
|
Case Rep Oncol
|
2013
|
0.83
|
|
30
|
UFP-101 antagonizes the spinal antinociceptive effects of nociceptin/orphanin FQ: behavioral and electrophysiological studies in mice.
|
Peptides
|
2006
|
0.82
|
|
31
|
Anxiolytic- and panicolytic-like effects of Neuropeptide S in the mouse elevated T-maze.
|
Eur J Neurosci
|
2012
|
0.82
|
|
32
|
VAMP-2, SNAP-25A/B and syntaxin-1 in glutamatergic and GABAergic synapses of the rat cerebellar cortex.
|
BMC Neurosci
|
2011
|
0.82
|
|
33
|
Urotensin II stimulates plasma extravasation in mice via UT receptor activation.
|
Naunyn Schmiedebergs Arch Pharmacol
|
2004
|
0.82
|
|
34
|
UFP-112 a potent and long-lasting agonist selective for the Nociceptin/Orphanin FQ receptor.
|
CNS Neurosci Ther
|
2010
|
0.81
|
|
35
|
Lack of a chemobrain effect for adjuvant FOLFOX chemotherapy in colon cancer patients. A pilot study.
|
Support Care Cancer
|
2012
|
0.81
|
|
36
|
Pharmacological characterisation of [(pX)Phe4]nociceptin(1-13)amide analogues. 1. In vitro studies.
|
Naunyn Schmiedebergs Arch Pharmacol
|
2002
|
0.78
|
|
37
|
Further studies on the pharmacological features of the nociceptin/orphanin FQ receptor ligand ZP120.
|
Peptides
|
2008
|
0.78
|
|
38
|
In vitro and in vivo pharmacological characterization of the nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-ol.
|
Eur J Pharmacol
|
2006
|
0.76
|
|
39
|
Vasoactive intestinal polypeptide immunoreactivity in the human cerebellum: qualitative and quantitative analyses.
|
J Anat
|
2009
|
0.75
|
|
40
|
Calbindin-D28K immunoreactivity in the human cerebellar cortex.
|
Anat Rec (Hoboken)
|
2014
|
0.75
|